Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Idiopathic Pulmonary Arterial Hypertension
NCT05493371Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in idiopathic pulmonary arterial hypertension (IPAH), sponsored by Amsterdam University Medical Center. Primary endpoints: Tolerability at 12 weeks, Feasibility at 12 weeks and 1 more. Started Mar 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
idiopathic pulmonary arterial hypertension (IPAH)
Beyond the preview
Go deeper on NCT05493371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493371.